Odyssey Therapeutics (ODTX) analyst forecast and price target
Analyst forecast
Consensus of 6 analyst ratings
Based on 4 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| UBS | Initiated Coverage | Buy | $27.00 | Oct 12, 2026 |
| Raymond James | Initiated Coverage | Outperform | $42.00 | Oct 9, 2026 |
| HC Wainwright & Co. | Initiated Coverage | Buy | $44.00 | Aug 27, 2026 |
| JP Morgan | Maintained | Overweight | $29.00 from $26.00 | Aug 7, 2026 |
| Oppenheimer | Maintained | Outperform | $40.00 | Jun 18, 2026 |
| Wedbush | Initiated Coverage | Outperform | $30.00 | Jun 2, 2026 |
| Cantor Fitzgerald | Initiated Coverage | Overweight | — | Jun 2, 2026 |
| TD Cowen | Initiated Coverage | Buy | — | Jun 2, 2026 |
| JP Morgan | Initiated Coverage | Overweight | $26.00 | Jun 2, 2026 |
| Oppenheimer | Initiated Coverage | Outperform | $40.00 | Jun 2, 2026 |
Frequently asked questions
What is the price target for ODTX stock?
The average 12-month analyst price target for Odyssey Therapeutics (ODTX) is $35.50, with a high estimate of $44.00 and a low of $27.00, across 4 analysts.
Is ODTX a buy, sell, or hold?
Analysts covering Odyssey Therapeutics currently average a Buy rating: 6 buy, 0 hold and 0 sell, from 6 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for ODTX?
The average price target of $35.50 implies 102.05% upside from the last price of $17.57.
What is the latest analyst rating on ODTX?
On Oct 12, 2026, UBS initiated coverage of Odyssey Therapeutics at Buy with a price target of $27.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.